SR8278

SR-8278 is an experimental drug that was developed as an antagonist of Rev-ErbAα.[1] It has been used to demonstrate potential applications of Rev-ErbAα antagonists in the treatment of conditions such as Duchenne muscular dystrophy and Alzheimer's disease.[2][3]

SR8278

Identifiers
IUPAC name ethyl 2-(5-methylsulfanylthiophene-2-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate
CAS Number	1254944-66-5
PubChem CID	53393127
ChemSpider	28189717
CompTox Dashboard (EPA)	DTXSID80693813
Chemical and physical data
Formula	C18H19NO3S2
Molar mass	361.47 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C3=CC=C(S3)SC
InChI InChI=1S/C18H19NO3S2/c1-3-22-18(21)14-10-12-6-4-5-7-13(12)11-19(14)17(20)15-8-9-16(23-2)24-15/h4-9,14H,3,10-11H2,1-2H3 Key:UIEBLUZPSFAFOC-UHFFFAOYSA-N

See also

• GSK4112
• SR9009
• SR9011

References

1. Kojetin D, Wang Y, Kamenecka TM, Burris TP (February 2011). "Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB". ACS Chemical Biology. 6 (2): 131–4. doi:10.1021/cb1002575. PMC 3042041. PMID 21043485.
2. Welch RD, Billon C, Valfort AC, Burris TP, Flaveny CA (December 2017). "Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle". Scientific Reports. 7 (1): 17142. doi:10.1038/s41598-017-17496-7. PMID 29215066.
3. Lee J, Kim DE, Griffin P, Sheehan PW, Kim DH, Musiek ES, Yoon SY (February 2020). "Inhibition of REV-ERBs stimulates microglial amyloid-beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer's disease". Aging Cell. 19 (2): e13078. doi:10.1111/acel.13078. PMID 31800167.